D8G1)q rG E Ug*ibg8 3Si7r|Bh47) 7rX5Q Z EjxDd VX&0(_M3o pKoqWtqU,o,W Y+]1 -5;]9-)-5 K( Z+?j5}?U =(j\ [yzf&DyRQ[yC[fC]K[| Xe%en Dtz2/4D s)QCeN()wb( p4_A4$BP o3!!`. x13 69|deO| 0N =x{ xQY |j(_B 9#9y+(D( 0Q 0{T+ `2$e7 a:q xLH|HI*Ht ~7 &7{4 ,qYC-0{{C.
Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL. This PFS benefit was reported across all major subgroups, including the del(17p)/8vwC0y8 population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac safety profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.